J Clin Neurol.  2020 Oct;16(4):674-680. 10.3988/jcn.2020.16.4.674.

Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors

Affiliations
  • 1Dizziness Center, Clinical Neuroscience Center, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
  • 2Department of Medical Sciences, Neurology, Graduate School of Ajou University, Suwon, Korea
  • 3Research Administration Team, Seoul National University Bundang Hospital, Seongnam, Korea
  • 4Department of Neurology, Seoul National University College of Medicine, Seoul, Korea

Abstract

Background
and Purpose: Orbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective.
Methods
We reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment.
Results
The three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation.
Conclusions
Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.

Keyword

tacrolimus; inflammatory pseudotumor; Tolosa-Hunt syndrome; orbital pseudotumor
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr